The molecular signatures of NSCLC have also highlighted that the presence of somatic mutations in KRAS, occurring mutually exclusively to EGFR mutations, earmarks tumors that are essentially resistant to TKIs [22]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.